Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc.GALE · Entity 4313 | Director | October 10, 2017 | October 10, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SELLAS Life Sciences Group, Inc.
Report date October 10, 2017 · Filed October 10, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,690 |
Reported balance
After 2017-10-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-10-10 · Grant · Acquired 14,366 · Balance 34,690 F1: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2: Represents the closing stock price of the Company's stock on the first trading day of the quarter. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter.
F2: Represents the closing stock price of the Company's stock on the first trading day of the quarter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 10, 2017 Filed Oct 10, 2017 21:51 UTC | SELLAS Life Sciences Group, Inc. GALE · Entity 4313 | GrantCommon Stock | 14,366 | $0.38 | $5,459.08 |
DisclosureSEC source: 0001394548-17-000029 · primary_doc.xml · nonDerivative · entry 1 Einhorn Irving M. · CIK 0001603271 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,690 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| July 06, 2017 Filed Jul 6, 2017 21:47 UTC | SELLAS Life Sciences Group, Inc. GALE · Entity 4313 | GrantCommon Stock | 9,161 | $0.59 | $5,404.99 |
DisclosureSEC source: 0001394548-17-000026 · primary_doc.xml · nonDerivative · entry 1 Einhorn Irving M. · CIK 0001603271 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,114 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be pain in unrestricted shares of the Company's common stock delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| June 08, 2017 Filed Jul 6, 2017 21:47 UTC | SELLAS Life Sciences Group, Inc. GALE · Entity 4313 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001394548-17-000026 · primary_doc.xml · derivative · entry 2 Einhorn Irving M. · CIK 0001603271 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-06-08 F3 · security: Granted pursuant to the Issuer's 2016 Incentive Plan. F4 · derivative.exercise_date: This stock option will vest and become exercisable in equal quarterly installments over one year beginning three months from June 8, 2017, such that the option will be fully exercisable as of June 8, 2018. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 20:59 UTC | SELLAS Life Sciences Group, Inc. GALE · Entity 4313 | GrantCommon Stock | 8,638 | $0.59 | $5,096.42 |
DisclosureSEC source: 0001394548-17-000014 · primary_doc.xml · nonDerivative · entry 1 Einhorn Irving M. · CIK 0001603271 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,953 F1 · security: Effective January 1, 2017, 33% of the cash retainer payment to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| January 20, 2017 Filed Jan 25, 2017 00:27 UTC | SELLAS Life Sciences Group, Inc. GALE · Entity 4313 | GrantCommon Stock | 2,525 | $1.98 | $4,999.50 |
DisclosureSEC source: 0001394548-17-000010 · primary_doc.xml · nonDerivative · entry 1 Einhorn Irving M. · CIK 0001603271 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,525 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.